All data are based on the daily closing price as of June 6, 2025
a
Astellas Pharma
4503.TSE
9.69 USD
-0.06
-0.62%
Overview
Last close
9.69 usd
Market cap
17.34B usd
52 week high
12.40 usd
52 week low
8.65 usd
Target price
12.27 usd
Valuation
P/E
49.5035
Forward P/E
12.3457
Price/Sales
1.3068
Price/Book Value
1.6514
Enterprise Value
21.49B usd
EV/Revenue
1.6274
EV/EBITDA
12.5465
Key financials
Revenue TTM
13.20B usd
Gross Profit TTM
10.79B usd
EBITDA TTM
2.98B usd
Earnings per Share
0.19 usd
Dividend
0.51 usd
Total assets
22.40B usd
Net debt
4.31B usd
About
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. Astellas Pharma Inc. was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. The company was founded in 1923 and is headquartered in Tokyo, Japan.